Cargando…

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design

INTRODUCTION: The Alzheimer's biomarkers in daily practice (ABIDE) project is designed to translate knowledge on diagnostic tests (magnetic resonance imaging [MRI], cerebrospinal fluid [CSF], and amyloid positron emission tomography [PET]) to daily clinical practice with a focus on mild cogniti...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Wilde, Arno, van Maurik, Ingrid S., Kunneman, Marleen, Bouwman, Femke, Zwan, Marissa, Willemse, Eline A.J., Biessels, Geert Jan, Minkman, Mirella, Pel, Ruth, Schoonenboom, Niki S.M., Smets, Ellen M.A., Wattjes, Mike P., Barkhof, Frederik, Stephens, Andrew, van Lier, Erik J., Batrla-Utermann, Richard, Scheltens, Philip, Teunissen, Charlotte E., van Berckel, Bart N.M., van der Flier, Wiesje M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Diagnostic Assessment & Prognosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318541/ https://www.ncbi.nlm.nih.gov/pubmed/28239639 http://dx.doi.org/10.1016/j.dadm.2017.01.003

Ejemplares similares

Clinician-patient communication during the diagnostic workup: The ABIDE project
por: Visser, Leonie N.C., et al.
Publicado: (2019)

Clinicians' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project
por: Kunneman, Marleen, et al.
Publicado: (2017)

Patients' and caregivers' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project
por: Kunneman, Marleen, et al.
Publicado: (2017)

ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics
por: Fruijtier, Agnetha D., et al.
Publicado: (2019)

Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease
por: van Maurik, Ingrid S, et al.
Publicado: (2019)

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
por: Willemse, Eline A.J., et al.
Publicado: (2018)

Clinicians’ communication with patients receiving a MCI diagnosis: The ABIDE project
por: Visser, Leonie N. C., et al.
Publicado: (2020)

Prediction of poor clinical outcome in vascular cognitive impairment: TRACE‐VCI study
por: Boomsma, Jooske M.F., et al.
Publicado: (2020)

What patients want to know, and what we actually tell them: The ABIDE project
por: Fruijtier, Agnetha D., et al.
Publicado: (2020)

Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project
por: Visser, Leonie N. C., et al.
Publicado: (2019)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial
por: Fruijtier, Agnetha D., et al.
Publicado: (2022)

Evaluating combinations of diagnostic tests to discriminate different dementia types
por: Bruun, Marie, et al.
Publicado: (2018)

Steeper memory decline after COVID-19 lockdown measures
por: Bakker, Els D., et al.
Publicado: (2023)

Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer’s disease
por: Ingala, Silvia, et al.
Publicado: (2022)

Diagnostic dilemmas in Alzheimer's disease: Room for shared decision making
por: van der Flier, Wiesje M., et al.
Publicado: (2017)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Biomarker testing in MCI patients—deciding who to test
por: van Maurik, Ingrid S., et al.
Publicado: (2021)

Cerebral perfusion in the predementia stages of Alzheimer’s disease
por: Binnewijzend, Maja A. A., et al.
Publicado: (2015)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia
por: Zwan, Marissa D., et al.
Publicado: (2017)

Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging
por: Leijenaar, Jolien F., et al.
Publicado: (2017)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease
por: Mank, Arenda, et al.
Publicado: (2022)

Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure
por: Cinca, Juan, et al.
Publicado: (2013)

Phase of Illness in palliative care: Cross-sectional analysis of clinical data from community, hospital and hospice patients
por: Mather, Harriet, et al.
Publicado: (2017)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

Prediction of thrombo‐embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk‐CVA)
por: Guttmann, Oliver P., et al.
Publicado: (2015)

MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2017)

Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non‐ischaemic dilated cardiomyopathy
por: Mirelis, Jesús G., et al.
Publicado: (2022)

The Ocular Trauma Score
por: Scott, Robert
Publicado: (2015)

Implementing and applying the Ocular Trauma Score: the challenges
por: Murray, Desirée C
Publicado: (2015)

A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redin‐SCORE
por: Álvarez‐García, Jesús, et al.
Publicado: (2015)

External validation and clinical utility of a prediction model for 6-month mortality in patients undergoing hemodialysis for end-stage kidney disease
por: Forzley, Brian, et al.
Publicado: (2017)

The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes
por: Rørth, Rasmus, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l0tefs2neljek74jefm6e0dqh6